

EXPAREL®

(bupivacaine liposome injectable suspension)

DENTAL AND ORAL SURGERY RESOURCES FOR EXPAREL




THE FIRST AND ONLY FDA-APPROVED LONG-ACTING LOCAL ANALGESIC FOR **AGES 6 AND ABOVE**.¹ [Click here](#) for more info

Informative resources are available for your review on www.exparel.com, including procedure videos and case reports


CLICK ON IMAGES BELOW TO LEARN MORE ▼

FAQs in Oral Surgery

If you have more questions about EXPAREL, visit our FAQ page to learn more.



Administrative Case Reports and Videos



Third molar extraction



Full maxillary reconstruction infiltration



Bilateral temporomandibular joint arthroplasty*



Patient and Care Team Resources

Additional resources to support your patients and practice.



Oral Surgery Toolkit

A tool kit is available to help you spread awareness and educate patients and the community about your non-opioid approach for managing postsurgical pain.





Reimbursement

Reimbursement codes for EXPAREL and related billing guidance are provided to ensure you have timely information.[†] To contact a dedicated Pacira reimbursement specialist:

Email reimbursement@pacira.com

Call the reimbursement helpline at **855-793-9727**



Surgeon Selector

A searchable database that allows patients to find health care providers, like you.

Register for Surgeon Selector to set your facility apart.



Order Now

Connect With Us

FDA=US Food and Drug Administration.

*A case report is also available through the link.

[†]Content for informational purposes only. Pacira cannot guarantee successful reimbursement for EXPAREL from the use of provided resources. Reimbursement criteria will vary by payer.

Please see Important Safety Information on next page. [CLICK HERE](#) for full Prescribing Information.

To learn more about EXPAREL in OMFS, visit
<https://www.exparel.com/hcp/specialty/oral-maxillofacial>



Indication

EXPAREL® (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in patients aged 6 years and older to produce postsurgical local analgesia and in adults as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported in adults with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

Adverse reactions with an incidence greater than or equal to 10% following EXPAREL administration via infiltration in pediatric patients six to less than 17 years of age were nausea, vomiting, constipation, hypotension, anemia, muscle twitching, vision blurred, pruritus, and tachycardia.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient populations: patients <6 years old for infiltration, patients younger than 18 years old for interscalene brachial plexus nerve block, and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks **other than interscalene brachial plexus nerve block**, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability, which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions: Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Methemoglobinemia: Cases of methemoglobinemia have been reported with local anesthetic use.

Full Prescribing Information is also available at www.EXPAREL.com.

OMFS=oral and maxillofacial surgery.

Reference: 1. Pacira BioSciences. Pacira announces FDA approval of supplemental new drug application for EXPAREL® (bupivacaine liposome injectable suspension) in pediatric patients [press release]. Pacira website. <https://investor.pacira.com/news-releases/news-release-details/pacira-announces-fda-approval-supplemental-new-drug-0>. Published March 22, 2021. Accessed May 23, 2023.